Evidence map›Paper›PMID 29998190›Full record

ArticleMolecular therapy oncolytics2018

Preclinical Development of Oncolytic Immunovirotherapy for Treatment of HPV

Lukkana Suksanpaisan, Rong Xu, Mulu Z Tesfay, Carolyn Bomidi, Stefan Hamm, Rianna Vandergaast, Nathan Jenks, Michael B Steele, Ayuko Ota-Setlik, Hinna Akhtar and 7 more

Open access · goldAbstract read
In one paragraph

Article in Molecular therapy oncolytics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Oncolytic Viruses: Priming Time for Cancer Immunotherapy.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 3 institutions in 1 country.

Lukkana SuksanpaisanImanis Life Sciences, Rochester, MN 55902, USA.
Rong XuProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Mulu Z TesfayImanis Life Sciences, Rochester, MN 55902, USA.
Carolyn BomidiImanis Life Sciences, Rochester, MN 55902, USA.
Stefan HammProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Rianna VandergaastImanis Life Sciences, Rochester, MN 55902, USA.
Nathan JenksToxicology and Pharmacology Laboratory, Mayo Clinic, Rochester, MN 55905, USA.
Michael B SteeleToxicology and Pharmacology Laboratory, Mayo Clinic, Rochester, MN 55905, USA.
Ayuko Ota-SetlikProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Hinna AkhtarProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Amara LuckayProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Rebecca NowakProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Kah Whye PengToxicology and Pharmacology Laboratory, Mayo Clinic, Rochester, MN 55905, USA.
John H EldridgeProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
David K ClarkeProfectus Biosciences, Inc., Pearl River, NY 10965, USA.
Stephen J RussellVyriad, Inc., Rochester, MN 55902, USA.
Rosa Maria DiazVyriad, Inc., Rochester, MN 55902, USA.
Profectus Biosciences (United States) · USUniversity of Minnesota Rochester · USMayo Clinic in Arizona · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Immunotherapy for HPV

Indexed as

HPV positive cancerpreclinicalVSV immunovirotherapy

Identifiers

PMID29998190
PMCPMC6037044
OpenAlexW2850990132

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.